Issue link: http://osercommunicationsgroup.uberflip.com/i/668581
C h a i n D r u g s t o r e D a i l y M o n d a y, A p r i l 1 8 , 2 0 1 6 4 SUN PHARMA: PROFILE OF AN EMERGING GLOBAL LEADER Sun Pharma is the world's fifth largest specialty generic and India's top pharma- ceutical company, with a vertically inte- grated business, economies of scale, an extremely skilled team enabling delivery of quality products at affordable prices and is trusted by customers and patients in over 150 countries globally. Sun Pharma's global presence is supported by 49 manufacturing facilities spread across six continents, R&D centers worldwide and a multi-cultural workforce represent- ing more than 50 nationalities. Sun Pharma fosters excellence through innovation, supported by strong R&D capabilities. Its early investments in R&D, beginning three decades ago, enabled it to make technology its key dif- ferentiator and develop a basket of robust products for diverse markets across the world. The company has the capability to deliver affordable and quality products within established timelines by develop- ing generics and technologically com- plex products through focused teams in formulations, process chemistry and ana- lytical development. A team of nearly 2,000 research sci- entists across Sun Pharma's R&D centers worldwide are equipped with cutting- edge technologies and expertise in devel- oping generics, difficult to make technol- ogy intensive products, Active Pharmaceutical Ingredients (APIs), Novel Drug Delivery Systems (NDDS) and New Chemical Entities (NCEs). These scientists work closely with the business development team to generate innovative concepts and ideas, exploiting both market needs and synergies across various therapeutic areas. Sun Pharma invests around seven percent of its annu- al revenues in research, and its R&D pro- ductivity ranks highest among Indian generic companies. Sun Pharma's manufacturing opera- tions are focused on producing generics, branded generics, specialty, over-the- counter (OTC) products, anti-retrovirals (ARVs), Active Pharmaceutical Ingredients (APIs) and intermediates in the full range of dosage forms, including tablets, capsules, injectables, ointments, creams and liquids. It also manufactures specialty APIs, including controlled sub- stances, steroids, peptides and anti-can- cers. The company has a highly skilled team of regulatory affairs specialists who are well versed with regulatory policies and procedures around the world. They have a wealth of experience in the timely filing of dossiers, as well as han- dling regulatory queries from both authorities and customers. Sun Pharma's manufacturing facili- ties are routinely inspected by interna- tional regulatory authorities. Several reg- ulatory agencies, including FDA-USA, EMA-Europe, MHRA-UK, MCC-South Africa, TGA-Australia, ANVISA-Brazil, WHO-Geneva, BfArM-Germany, KFDA-Korea and PMDA-Japan have certified its facilities. The consolidated revenues for 12 months ending March 31, 2015 were approximately US$4.5 billion, of which U.S. contributed US$ 2.2 billion. In India, Sun Pharma enjoys leadership across 13 different classes of doctors with 30 brands featuring among top 300 pharmaceutical brands. Its footprint across emerging markets covers more than 100 markets and six markets in Western Europe. The Global Consumer Healthcare business is ranked among Top 10 across four global markets, and the API business footprint is strengthened through 14 world class API manufactur- ing facilities world over. Visit Sun Pharma at booth #652. AMNEAL EXPANDS INFRASTRUCTURE AND CAPACITY In the past year, Amneal has invested heavily in expanding its manufacturing and packaging capacity, both in the U.S. and abroad. These infrastructure invest- ments will enable the company to signif- icantly increase capacity by the end of 2016, satisfying the production needs of its sizable pipeline across several new dosage forms, including oncology injectables, injectables, nasal sprays, top- icals, inhalers and transdermals. "Amneal has always invested heavi- ly, with a disproportionate percentage of its revenue, in growing and broadening our product portfolio across all dosage forms and therapeutic categories," says Jim Luce, Executive Vice President of Marketing and Sales. "Simultaneously, we've continued to expand and enhance our infrastructure to plan for future growth, ensuring our capacity is able to meet our anticipated product approvals." Currently, Amneal owns a total of nine U.S. FDA-compliant facilities, with another three in progress. The company has spent approximately $327 million in 2015 alone on capital investments, research and development and acquisi- tions, all of which are fueling the rapid expansion. Amneal is also expanding its global commercial presence and has uncovered opportunities to bolster its total infra- structure/capacity. The company now has a commercial presence in Australia, the U.K., Netherlands, Scandinavia, Germany and Spain, with its internation- al headquarters in Switzerland. Most of these foreign entities were acquisitions of companies with established product lines, which will continue to grow by incorporating the Amneal label into their product portfolio. Amneal's expansion in India includes R&D, API for self-consumption and man- ufacturing capabilities to accommodate increased pro- duction for the i n t e r n a t i o n a l markets as well as meet incre- mental U.S. demand. "Our success is primarily tied to our sharp focus on our growth strategy and the significant investments in R&D and infrastructure," says Luce. "Our commitment to delivering value to our customers is rooted in the company's core principles of high-touch customer service, transparency, integrity and quality. We believe in developing mean- ingful business relationships rather than transactional ones – a belief that runs across the company from our Chief Executive Officers all the way through to the individual who picks, packs and ships an order to a customer." Most recently, in 2015, Amneal pur- chased the former Johnson & Johnson facility in Cashel, Ireland, which is in Tipperary County in the southeast region of the country. The facility will be dedi- cated to R&D and the commercial pro- duction of metered dose and dry powder inhalers as well as hormonal injectables, all high-end specialty medications. Once inspected and on-line, the facility will be the 10th U.S. FDA-approved site for Amneal. One thing to note is that while Amneal continues its steady growth, it remains steadfastly committed to its core guideline of doing so smartly, in a way that aligns with the company's overall strategy and not simply for the sake of growth. "Amneal will never compromise quality for profit. This commitment to quality stems from our guiding principle to view the consumer of our products like a family member," Luce says. "This belief permeates throughout the organi- zation, instilling great confidence among our customers." Visit Amneal at booth #202 or go to www.amneal.com to learn more. AN INDEPENDENT PUBLICATION NOT AFFILIATED WITH NACDS Lee M. Oser CEO and Editor-in-Chief Jules Denton Kim Forrester Delaney Oser Associate Publishers Lorrie Baumann Editorial Director Jeanie Catron JoEllen Lowry Associate Editors André Gressieux Art Director Yasmine Brown Krystal Robles Graphic Designers Caitlyn McGrath Sarah Glenn Customer Service Managers Stacy Davis Kim Stevens Show Logistics & Distribution James Gennette John Pechota Carlos Velasquez Account Managers Enrico Cecchi European Sales Chain Drugstore Daily is published by Oser Communications Group ©2016 All rights reserved. Executive and editorial offices at: 1877 N. Kolb Road, Tucson, AZ 85715 520.721.1300/Fax: 520.721.6300 www.osercommunicationsgroup.com European offices located at Lungarno Benvenuto Cellini, 11, 50125 Florence, Italy NEXCARE GIVE PROGRAM ENCOURAGES GIVING BLOOD Nexcare™ Brand, in partnership with American Red Cross and America's Blood Centers, announces its eighth annual Give program. Timed to the World Health Organization's World Blood Donor Day on June 14, the pro- gram aims to spread awareness about the importance of blood donation and encourage people to get involved. The theme for this year's program is "Feel the Beat, Give Blood" and features a collection of limited-edition bandages with vibrant dance-inspired designs, reflecting unique styles and cultures from around the world. The bandages will be available for free to donors at participat- ing American Red Cross and America's Blood Centers donor sites and blood drives around the country, kicking off Monday, June 6 and rolling out through- out the week leading up to World Blood Donor Day. They will also be available as a bonus in select Nexcare Waterproof Bandage packs at retailers nationwide and online at www.nex- caregive.com. Every two seconds, someone in the U.S. needs blood. The sum- mer months are a critical time each year for blood donation. Throughout this period, the blood centers face what are known as "summer shortages." The Nexcare Give Program aims to spark the conversation around World Blood Donor Day, with the goal that through educating people nationwide and continuing to raise awareness, there can be an ample supply of blood in centers across the country for those in need. With these seasonal dis- tractions, fewer people give blood, and consequently the centers face a greater need for blood donation. Pledge to support blood donation, locate a blood cen- ter nearby and sign up to receive free Nexcare Give Bandages by mail by visiting www.nexcaregive.com. Those who wish to show support and share personal blood donation stories with the "Give" community are encour- aged to use the hashtag #GiveInspires in their posts, tweets and photos. For more information, visit Cabana 5 or go to www.nexcaregive.com.